China's Biopharma Industry Makes Innovation-driven Leap

China's biopharmaceutical industry is now shifting from scale-driven growth to innovation-led development. Chimeric antigen receptor, or CAR, T-cell therapy, is among the most advanced cancer treatments in the world. In east China's Nanjing City, this CAR T-cell therapy manufacturing facility under IASO Bio is one of the largest of its kind in the country. Here, every production step is digitally tracked with online monitoring, video surveillance and electronic barcode tracing to ensure the products' safety and effectiveness. Elsewhere in Nanjing City, this pharmaceutical company is home to six 10,000-liter stainless-steel bioreactor lines, with a localization rate of over 90 percent. The facility is the country's first approved production line for biosimilars at the 10,000-litre scale. According to company officials, their R&D investment has exceeded 2.6 billion U.S. dollars over the past five years, with more than 100 innovative drugs in clinical trials. Welcome to subscribe us on: Facebook: https://www.facebook.com/NewsContent.CCTVPLUS Twitter: https://twitter.com/CCTV_Plus LinkedIn: https://www.linkedin.com/company/cctv-news-content Instagram: https://www.instagram.com/cctv_video_news_agency/ TikTok: https://www.tiktok.com/@cctv_plus Video on Demand: www.cctvplus.com If you are in demand of this video footage, please contact with our business development team via email: [email protected], [email protected]